DOYLESTOWN, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Quigley Pharma, www.QuigleyPharma.com, a wholly owned subsidiary of The Quigley Corporation announced today that it has completed a preliminary follow up Cachexia study, evaluating weight loss in mice. The tumor burden Cachexia model study concluded that QR-443 was as effective in delaying the progression of Cachexia when given orally as it had been shown to be when administered intra-peritoneally in a previous study. The new data compliments the previous study results demonstrating a correlation between effectiveness and the frequency of administration of the QR-443 compound.
Cachexia is an extremely debilitating and life threatening, wasting syndrome associated with chronic diseases such as cancer, AIDs, chronic renal failure, COPD and rheumatoid arthritis, where inflammation has a significant impact and patients experience loss of weight, muscle atrophy, fatigue, weakness and decreased appetite.
The study model consisted of 4 groups of BALB/C mice being subjected to tumors resulting in Cachexia. All 4 groups (n=19) were fed 200 micro-liters phosphate buffered saline (PBS). Three groups were fed an established non-toxic 20 mg dose of the QR-443 compound at different dosing frequencies. The control group was fed (PBS) at the highest dosage frequency without QR-443. Results were determined by weighing each mouse over the course of the 27 day study. The weights of treated mice demonstrated a reduced progression of Cachexia corresponding to the frequency of dosing. Mice treated more frequently showed less weight loss and a delayed progression compared to mice treated less frequently. Untreated mice lost more weight and began losing that weight sooner than all three-treatment groups.
QR-443 has been shown in previous pre-clinical studies to inhibit the production of TNF-alpha and IFN-gamma and reduced other inflammatory cytokines associated with Cachexia.
Dr. Richard Rosenbloom, EVP/COO of Quigley Pharma, Inc. stated, “These findings in addition to previous work, show that the compound warrants continued research and development. The company will be preparing experiments to support the significance of this data with continued research.”
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will allow the aforementioned Compound to be tested in humans or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hyman G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com
Quigley Pharma
CONTACT: Media: Karen Pineman, G.S. Schwartz & Co., +1-212-725-4500,kpineman@schwartz.com; or Investors: Carl Hyman, G.S. Schwartz & Co.,+1-212- 725-4500, carlh@schwartz.com
Web site: http://www.QuigleyPharma.com/
